Generix Group (GENX.PA) Stock Price
Generix Group Price
Generix Group (GENX.PA) Stock | ISIN FR0010501692 | WKN A0MYAC. Generix Group operates in the Information technology sector.
Generix Group stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Generix Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Generix Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Generix Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Generix Group Price |
|---|
Generix Group Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Generix Group Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M EUR) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M EUR) |
| NET INCOME (M EUR) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Generix Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Generix Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Generix Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Generix Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Generix Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Generix Group stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Generix Group Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Generix Group business model & stock analysis
Generix Group SWOT Analysis
Strengths
Generix Group SA possesses several strengths that contribute to its success in the market. These include:
- Strong Market Presence: Generix Group SA has established a solid presence in the industry, with a wide customer base and a reputable brand.
- Product Innovation: The company is known for its continuous investment in research and development, resulting in innovative and cutting-edge solutions.
- Skilled Workforce: Generix Group SA has a highly skilled and experienced workforce that enables efficient operations and effective customer support.
- Global Footprint: With an international presence, Generix Group SA has the opportunity to tap into diverse markets and expand its reach.
Weaknesses
Despite its strengths, Generix Group SA also has several weaknesses that may hinder its growth and competitiveness. These include:
- Dependency on Key Customers: The company relies heavily on a few major clients, which creates vulnerability in case of loss or dissatisfaction of these customers.
- Limited Product Portfolio: Generix Group SA's product offerings are primarily focused on specific segments, limiting its ability to cater to a broader range of industries and customer needs.
- High Reliance on Technology: The company heavily relies on technology for its solutions, making it susceptible to disruptions or technological advancements that may render its products obsolete.
- Competitive Market: Generix Group SA faces intense competition from other industry players, which may impact its market share and profitability.
Opportunities
Generix Group SA has identified several opportunities that can be leveraged to its advantage. These include:
- Emerging Markets: Expansion into emerging markets presents significant growth opportunities for Generix Group SA, where demand for its solutions may be high.
- Digital Transformation: The increasing need for digital transformation in various industries provides a chance for Generix Group SA to offer its innovative solutions to companies seeking to modernize their operations.
- Partnerships and Collaborations: The company can form strategic partnerships and collaborations with other organizations to expand its product offerings, access new markets, and enhance its competitive position.
- Trends in Supply Chain Management: The evolving trends in supply chain management, such as e-commerce and omnichannel retailing, create opportunities for Generix Group SA to develop tailored solutions to meet changing customer demands.
Threats
Alongside opportunities, Generix Group SA also faces certain threats that may impact its business negatively. These threats include:
- Changing Regulatory Environment: Compliance with evolving regulations and policies can pose challenges for Generix Group SA, requiring constant monitoring and adaptation.
- Economic Instability: Economic downturns or recessions in key markets may impact customer spending and reduce demand for the company's solutions.
- New Entrants and Competitors: The entrance of new competitors or the expansion of existing competitors' offerings may intensify competition and potentially erode Generix Group SA's market share.
- Rapid Technological Changes: The rapid pace of technological advancements requires Generix Group SA to continually invest in research and development to stay ahead of competitors and meet customer expectations.
Generix Group Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Generix Group historical P/E ratio, EBIT multiple, and P/S ratio
Generix Group annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Generix Group shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Generix Group shareholder structure
| % | Name |
|---|---|
55.58542% | |
5.64613% | |
3.5614% | |
2.20485% | |
1.37742% | |
1.07563% | |
1.06193% | |
0.95842% | |
0.90948% | |
0.79123% |
Generix Group Executives and Management Board
Mr. Jean-Charles Deconninck
(62)Chairman of the Management Board
Mrs. Aida Collette-Sene
Chief Executive Officer, Managing Director, Member of the Management Board
Mr. Ludovic Luzza
(43)Group Administrative and Financial Director, Member of the Management Board
Mr. Francois Poirier
(62)Chairman of the Supervisory Board · since 2002
Mr. Dominique Despiney
(70)Independent Vice Chairman of the Supervisory Board
Frequently asked questions about Generix Group
The main competitors of Generix Group SA in the market include companies like SAP SE, Oracle Corporation, IBM Corporation, and Infor, among others.
Generix Group stock
Generix Group Peer Group
Generix Group Ticker
Generix Group FIGI
All fundamentals and in-depth analysis of Generix Group
Our stock analysis for Generix Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Generix Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.